iCAIR project: battling infection and resistance
These days, even a “simple” infection can become a deadly threat. Bacteria keep developing new resistances to antibiotics, presenting the international medical community with a significant problem. There is a desperate need for new medications. The biggest hurdle in developing these new medications is getting them from the laboratory into clinical trials, bridging the gap from the discovery of new agents to their development by the pharmaceutical industry into potential medications. In the iCAIR (Fraunhofer International Consortium for Anti-Infective Research) project, researchers from the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM have teamed up with colleagues from the Hannover Medical School (MHH) and Griffith University’s Institute for Glycomics (IfG) in Gold Coast, Australia, to close this gap and develop new anti-infective drugs.